EGFR and lung adenocarcinoma: 18 reported EGFR mutations in 61% of lung adenocarcinoma patients with brain metastases. Based on previous studies and our group's previous study, we conclude that patients with brain metastases harbor EGFR mutations more frequently than do those without, and that EGFR mutations are poor prognostic factors in stage IV patients with brain metastases 27.